A day after striking the latest in a series of its special "channel" collaborations, Intrexon has reloaded its bank account with a fresh $150 million infusion of cash, with significant added contributions from billionaire founder R.J. Kirk and his venture fund, Third Security.
Biotech billionaire RJ Kirk has hitched another therapeutic developer to his synthetic biology wagon at Intrexon. This time it's Fibrocell Science, an Exton, PA-based developer with a personalized cell therapy for "aesthetic dermatology" on the market.
Biotech startup Intrexon has expanded the synthetic biology shop's ties with drug developer Synthetic Biologics, picking up ownership in the partner as part of a deal focused on generating monoclonal antibodies for infectious diseases.
These days, it's good to have your own money to bank on when you're growing a biotech company. It's also extraordinarily rare. The following 15 venture round qualified as the top investments of the first half, as tracked by Thomson Reuters and the National Venture Capital Association.
Forbes' Matthew Herper went searching for biotech billionaires on the magazine's annual list of the 400 richest Americans but could only scrape together three names: Patrick Soon-Shiong, who sold
Randal J. Kirk made $1.2 billion when he sold New River and its attention deficit disorder drug to Shire. He stands to add to that fortune now that another biotech he's backed, Clinical Data, is